At present, the research and development of bispecific antibody drugs for tumor immunity emerges in an endless stream, mainly including T‐cell bridging bispecific antibodies (such as targeting CD3/EpCAM), bispecific antibodies based on PD‐1/PD‐L1‐based dual immune pathway regulation (such as targeting PD‐L1/CTLA‐4, PD‐L1/OX40, PD‐L1/CD47) and bispecific antibodies that block immune checkpoints and inhibitory molecules in the tumor microenvironment (such as targeting PD‐L1/TGF‐β) [21, 22]. Here, CD47 is linked to neoplasm.